Bicara Therapeutics (BCAX) Research & Development (2023 - 2026)

Bicara Therapeutics' Research & Development history runs 4 years deep, the most recent figure standing at $100000.0 for Q1 2026.

• On a quarterly basis, Research & Development fell 98.48% year-over-year to $100000.0 in Q1 2026; TTM through Mar 2026 was -$34.2 million, a 1325.37% decrease from a year earlier, with the FY2024 full-year figure at $8.2 million, down 73.15% from the prior year.
• Research & Development climbed to $100000.0 in Q1 2026 per BCAX's latest filing, from -$92.1 million in the prior quarter.
• Across five years, Research & Development topped out at $33.0 million in Q3 2025 and bottomed at -$92.1 million in Q4 2025.
• The 4-year median for Research & Development is $10.5 million (2023), against an average of -$182636.4.
• Biggest YoY gain for Research & Development was 130.43% in 2024; the steepest drop was 437.94% in 2024.
• Year by year, Research & Development stood at $10.5 million in 2023, then slumped by 437.94% to -$35.5 million in 2024, then plunged by 159.55% to -$92.1 million in 2025, then soared by 100.11% to $100000.0 in 2026.
• Per Business Quant, the three latest BCAX Research & Development figures stand at $100000.0 (Q1 2026), -$92.1 million (Q4 2025), and $33.0 million (Q3 2025).